Vertex Pharmaceuticals (BSP:VRTX34) Current Accrued Expense : R$11,359 Mil (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Vertex Pharmaceuticals Current Accrued Expense?

Vertex Pharmaceuticals's Current Accrued Expense for the quarter that ended in Dec. 2023 was R$11,359 Mil.

Vertex Pharmaceuticals's quarterly Current Accrued Expense increased from Jun. 2023 (R$12,610 Mil) to Sep. 2023 (R$14,358 Mil) but then declined from Sep. 2023 (R$14,358 Mil) to Dec. 2023 (R$11,359 Mil).

Vertex Pharmaceuticals's annual Current Accrued Expense increased from Dec. 2021 (R$7,164 Mil) to Dec. 2022 (R$9,381 Mil) and increased from Dec. 2022 (R$9,381 Mil) to Dec. 2023 (R$11,359 Mil).

Vertex Pharmaceuticals Current Accrued Expense Historical Data

The historical data trend for Vertex Pharmaceuticals's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vertex Pharmaceuticals Current Accrued Expense Chart

Vertex Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Current Accrued Expense

Get a 7-Day Free Trial

3,883.03

5,841.29

7,164.19

9,380.87

11,358.72

Vertex Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Current Accrued Expense	Get a 7-Day Free Trial															9,380.87	12,115.20	12,610.40	14,358.28	11,358.72

Vertex Pharmaceuticals Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Vertex Pharmaceuticals Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Vertex Pharmaceuticals's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Vertex Pharmaceuticals (BSP:VRTX34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vertex Pharmaceuticals Inc (BSP:VRTX34) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

VRTX:USA VRTX:Mexico 1VRTX:Italy VX1d:UK VX1:Germany VRTX:Austria

Address

50 Northern Avenue, Boston, MA, USA, 02210

Website

https://www.vrtx.com

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Vertex Pharmaceuticals (BSP:VRTX34) Headlines

No Headlines